Cover Image
Market Research Report

NORTH AMERICA BETA GLUCAN MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 636636
Published Content info 94 Pages
Delivery time: 1-2 business days
Price
Back to Top
NORTH AMERICA BETA GLUCAN MARKET FORECAST 2018-2026
Published: May 14, 2018 Content info: 94 Pages
Description

KEY FINDINGS

The North America beta glucan market is expected to progress at a 7.70% CAGR during the forecast period of 2018-2026. The unexploited beta glucan applications in cosmetic and medicine sector are expected to present this market with potential growth opportunities.

MARKET INSIGHTS

The pharmaceutical industry is an important end-user in the North American beta-glucan market. Other key end-users in this market include animal feed, personal care, and food and beverages industry. In 2017, the US market accounted for the highest share in the North America beta-glucan market. It was followed by the Canadian beta-glucan market, which is expected to progress at a CAGR of xx%. The country's growing diabetic population and increasing number of ongoing clinical trials are boosting its market growth.

COMPETITIVE INSIGHTS

Pharmacon Asa, Frutarom, Specialty Biotech Ltd, Alltech Biotechnology, Milliporesigma (Merck), Tate & Lyle Plc, Lesaffre Human Care, Cargill Inc, Super Beta Glucan, Kemin Industries and Kerry Group Plc are few of the established market companies in this region.

Table of Contents
Product Code: 17080

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. UNITED STATES TO WITNESS ROBUST GROWTH DURING THE FORECAST PERIOD
    • 3.2.2. PHARMACEUTICAL- MAJOR MARKET BY END-USER
    • 3.2.3. SOLUBLE BETA GLUCAN HELD MAJOR CHUNK OF THE MARKET BY CATEGORY
    • 3.2.4. CEREALS TO OFFER LUCRATIVE OPPORTUNITIES

4. MARKET DYNAMICS

  • 4.1. MARKET DEFINITION
  • 4.2. DRIVERS
    • 4.2.1. GROWING HEALTH CONCERN AMONG CONSUMERS AND INCREASING HEALTH EXPENDITURE
    • 4.2.2. GROWING APPLICATIONS OF BETA-GLUCAN IN THE FOOD INDUSTRY
    • 4.2.3. DECREASING PRICES OF MAJOR RAW MATERIAL SOURCES
  • 4.3. RESTRAINTS
    • 4.3.1. VARIOUS SIDE EFFECTS OF CONSUMING BETA GLUCAN
    • 4.3.2. INCONSISTENCY IN REGULATORY NORMS
  • 4.4. OPPORTUNITIES
    • 4.4.1. UNEXPLOITED BETA GLUCAN APPLICATIONS IN COSMETIC AND MEDICINE SECTOR
  • 4.5. CHALLENGES
    • 4.5.1. INCREASE IN COST OF BETA-GLUCAN EXTRACTION PROCESS

5. MARKET BY SOURCE

  • 5.1. BACTERIA
  • 5.2. FUNGUS
  • 5.3. YEAST
  • 5.4. CEREAL
  • 5.5. ALGAE

6. MARKET BY END-USERS

  • 6.1. FOOD AND BEVERAGES
  • 6.2. PERSONAL CARE
  • 6.3. PHARMACEUTICALS
  • 6.4. ANIMAL FEED

7. MARKET BY CATEGORY

  • 7.1. INSOLUBLE BETA GLUCAN
  • 7.2. SOLUBLE BETA GLUCAN

8. KEY ANALYTICS

  • 8.1. PORTER'S 5 FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. KEY BUYING CRITERIA
    • 8.2.1. COST
    • 8.2.2. NUTRITIONAL CONTENT
    • 8.2.3. SOURCE
    • 8.2.4. APPLICATIONS
  • 8.3. VALUE CHAIN ANALYSIS
    • 8.3.1. RAW MATERIAL SUPPLIERS
    • 8.3.2. MANUFACTURING
    • 8.3.3. DISTRIBUTORS/RETAILERS
    • 8.3.4. END-USERS
  • 8.4. REGULATORY FRAMEWORK
  • 8.5. KEY TRENDS
    • 8.5.1. RISING PREVALENCE OF DIABETES
    • 8.5.2. INVESTMENTS IN BETA GLUCAN
  • 8.6. INVESTMENT OUTLOOK
    • 8.6.1. END-USERS OUTLOOK
  • 8.7. VENDOR LANDSCAPE
  • 8.8. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. US
  • 9.2. CANADA

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
    • 10.1.1. CARGILL INC (US)
    • 10.1.2. TATE & LYLE (UK)
    • 10.1.3. KERRY GROUP PLC (ISRAEL)
    • 10.1.4. OHLY (GERMANY)
    • 10.1.5. KONINKLIJKE DSM N.V. (NETHERLANDS)
  • 10.2. COMPANY PROFILES
    • 10.2.1. ALLTECH BIOTECHNOLOGY
      • 10.2.1.1. OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
      • 10.2.1.4. STRATEGIC ANALYSIS
    • 10.2.2. CARGILL INC
      • 10.2.2.1. OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC ANALYSIS
    • 10.2.3. CHR. HANSEN A/S
      • 10.2.3.1. OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC ANALYSIS
    • 10.2.4. GARUDA INTERNATIONAL INC
      • 10.2.4.1. OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
      • 10.2.4.4. STRATEGIC ANALYSIS
    • 10.2.5. KEMIN INDUSTRIES
      • 10.2.5.1. OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
      • 10.2.5.3. STRATEGIC INITIATIVES
      • 10.2.5.4. SCOT ANALYSIS
      • 10.2.5.5. STRATEGIC ANALYSIS
    • 10.2.6. SPECIALTY BIOTECH LTD
      • 10.2.6.1. OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC ANALYSIS
    • 10.2.7. MILLIPORESIGMA (MERCK)
      • 10.2.7.1. OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. SCOT ANALYSIS
      • 10.2.7.4. STRATEGIC ANALYSIS
    • 10.2.8. OHLY
      • 10.2.8.1. OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. STRATEGIC INITIATIVES
      • 10.2.8.4. SCOT ANALYSIS
      • 10.2.8.5. STRATEGIC ANALYSIS
    • 10.2.9. TATE & LYLE PLC
      • 10.2.9.1. OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
      • 10.2.9.4. SCOT ANALYSIS
      • 10.2.9.5. STRATEGIC ANALYSIS
    • 10.2.10. SUPER BETA GLUCAN
      • 10.2.10.1. OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC ANALYSIS
    • 10.2.11. KONINKLIJKE DSM N.V.
      • 10.2.11.1. OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC ANALYSIS
    • 10.2.12. FRUTAROM
      • 10.2.12.1. OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC ANALYSIS
    • 10.2.13. KERRY GROUP PLC
      • 10.2.13.1. OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. STRATEGIC ANALYSIS
      • 10.2.13.4. SCOT ANALYSIS
      • 10.2.13.5. STRATEGIC ANALYSIS
    • 10.2.14. LESAFFRE HUMAN CARE
      • 10.2.14.1. OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. SCOT ANALYSIS
      • 10.2.14.4. STRATEGIC ANALYSIS
    • 10.2.15. PHARMACON ASA
      • 10.2.15.1. OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. STRATEGIC INITIATIVES
      • 10.2.15.4. SCOT ANALYSIS
      • 10.2.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • TABLE 1 NORTH AMERICA BETA GLUCAN MARKET BY COUNTRY 2018-2026 ($ MILLION)
  • TABLE 2 APPLICATIONS OF DIFFERENT BETA GLUCAN IN FOOD PRODUCTION
  • TABLE 3 NORTH AMERICA BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • TABLE 4 NORTH AMERICA BETA GLUCAN MARKET BY END-USERS 2018-2026 ($ MILLION)
  • TABLE 5 NORTH AMERICA BETA GLUCAN MARKET BY CATEGORY 2018-2026 ($ MILLION)
  • TABLE 6 INVESTMENTS IN BETA GLUCAN
  • TABLE 7 NORTH AMERICA BETA GLUCAN MARKET BY COUNTRY ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • FIGURE 2 UNITED STATES BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 3 NORTH AMERICA SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 4 NORTH AMERICA CEREALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 5 EVOLUTION OF BETA-GLUCAN MARKET
  • FIGURE 6 GROWING HEALTHCARE EXPENDITURE IN UNITED STATES ($ PER CAPITA)
  • FIGURE 7 HEALTHCARE SPENDING PER CAPITA IN 2015 AND 2016
  • FIGURE 8 FUNCTIONAL FOOD AND BEVERAGES SALES IN BRAZIL 2009-2015 ($ BILLION)
  • FIGURE 9 COMMODITY PRICE INDEX OF WHEAT CROPS
  • FIGURE 10 NORTH AMERICA COSMETICS PRODUCTS MARKET 2015 ($ BILLION)
  • FIGURE 11 NORTH AMERICA BACTERIA MARKET 2018-2026 ($ MILLION)
  • FIGURE 12 NORTH AMERICA FUNGUS MARKET 2018-2026 ($ MILLION)
  • FIGURE 13 NORTH AMERICA YEAST MARKET 2018-2026 ($ MILLION)
  • FIGURE 14 NORTH AMERICA CEREAL MARKET 2018-2026 ($ MILLION)
  • FIGURE 15 NORTH AMERICA ALGAE MARKET 2018-2026 ($ MILLION)
  • FIGURE 16 NORTH AMERICA FOOD AND BEVERAGES MARKET 2018-2026 ($ MILLION)
  • FIGURE 17 NORTH AMERICA PERSONAL CARE MARKET 2018-2026 ($ MILLION)
  • FIGURE 18 NORTH AMERICA PHARMACEUTICALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 19 NORTH AMERICA ANIMAL FEED MARKET 2018-2026 ($ MILLION)
  • FIGURE 20 NORTH AMERICA INSOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 21 NORTH AMERICA SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 22 TOP 10 COUNTRIES WITH NUMBER OF PEOPLE LIVING WITH DIABETES IN MILLION (2015)
  • FIGURE 23 PERCENTAGE INCREMENT OF DIABETES ACROSS REGIONS (2015 TO 2040)
  • FIGURE 24 INVESTMENT PROPOSITION FOR NORTH AMERICA BETA GLUCAN MARKET BY END-USERS - 2017
  • FIGURE 25 UNITED STATES BETA GLUCAN MARKET 2018-2026
  • FIGURE 26 CANADA BETA GLUCAN MARKET 2018-2026
  • FIGURE 27 MARKET SHARE ANALYSIS OF TOP COMPANIES IN NORTH AMERICA BETA GLUCAN MARKET - 2017 (%)
Back to Top